Physician profile
Michael Lance Calub
NPI 1831933845
$2,160.15
in general payments reported to CMS, 2019-2025
30 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.20 |
| Education | $194.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $456.42 | 2025 | Erleada, Tecvayli, Darzalex |
| Gilead Sciences, INC. | $179.82 | 2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $155.28 | 2025 | Enhertu, Imfinzi, Tagrisso |
| Incyte Corporation | $116.16 | 2025 | Jakafi, Niktimvo |
| Array Biopharma INC | $102.66 | 2025 | Lorbrena, Mektovi, Braftovi |
| Seagen INC. | $99.00 | 2025 | |
| Pfizer INC. | $92.36 | 2025 | |
| Eisai INC. | $86.72 | 2025 | |
| Tersera Therapeutics LLC | $76.22 | 2025 | Zoladex, Xermelo |
| Takeda Pharmaceuticals U.S.A., INC. | $66.39 | 2025 | Fruzaqla, Iclusig |
| Novartis Pharmaceuticals Corporation | $65.44 | 2025 | |
| Abbvie INC. | $62.03 | 2025 | |
| Exelixis INC. | $55.58 | 2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $53.32 | 2025 | Onivyde, Somatuline Depot |
| Kyowa Kirin, INC. | $51.79 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $51.64 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.75 | 2025 | |
| Daiichi Sankyo INC. | $34.93 | 2025 | Enhertu |
| Deciphera Pharmaceuticals INC. | $33.16 | 2025 | Qinlock, Romvimza |
| Taiho Oncology, INC. | $31.03 | 2025 | Inqovi, Lonsurf |
| Celgene Corporation | $28.55 | 2025 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $27.91 | 2025 | Ultomiris |
| Octapharma USA, INC. | $27.33 | 2025 | Panzyga |
| E.R. Squibb & Sons, L.L.C. | $25.94 | 2025 | Opdualag |
| Sun Pharmaceutical Industries INC. | $25.33 | 2025 | |
| Genzyme Corporation | $24.51 | 2025 | |
| Geron Corporation | $23.83 | 2025 | Rytelo |
| Helsinn Therapeutics (U.S.), INC. | $21.29 | 2025 | Akynzeo |
| Glaxosmithkline, LLC. | $19.10 | 2025 | Blenrep |
| Sumitomo Pharma America, INC. | $18.66 | 2025 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Calub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.